Thrombin Inhibitor Market is Estimated to Witness High Growth Owing to Rising Prevalence of Cardiovascular Diseases
The thrombin inhibitor market consists of anticoagulant or blood thinner medications that inhibit the activation of thrombin. Thrombin plays a central role in coagulation as it converts fibrinogen into fibrin monomers and stimulates platelet aggregation. Thrombin inhibitors are used for the treatment and prevention of conditions with increased risk of blood clots such as deep vein thrombosis and pulmonary embolism. They are also used in patients undergoing surgery to reduce the risk of clot formation.
The global thrombin inhibitor market is estimated to be valued at US$ 30.75 billion in 2023 and is expected to reach US$ 46.85 billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030
Key Takeaways
Key players operating in the thrombin inhibitor market are Pfizer Inc., Bristol Myers Squibb, Bayer AG, Sanofi S.A., Boehringer Ingelheim GmbH, Johnson and Johnson, Daiichi Sankyo Company, Li
The thrombin inhibitor market consists of anticoagulant or blood thinner medications that inhibit the activation of thrombin. Thrombin plays a central role in coagulation as it converts fibrinogen into fibrin monomers and stimulates platelet aggregation. Thrombin inhibitors are used for the treatment and prevention of conditions with increased risk of blood clots such as deep vein thrombosis and pulmonary embolism. They are also used in patients undergoing surgery to reduce the risk of clot formation.
The global thrombin inhibitor market is estimated to be valued at US$ 30.75 billion in 2023 and is expected to reach US$ 46.85 billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030
Key Takeaways
Key players operating in the thrombin inhibitor market are Pfizer Inc., Bristol Myers Squibb, Bayer AG, Sanofi S.A., Boehringer Ingelheim GmbH, Johnson and Johnson, Daiichi Sankyo Company, Li
3 months ago
